Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma

24 September 2026 · By · Wire by Fusion42

Published

24 September 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at urologytimes.com →

◆ Verified

Fusion42 · 24 September 2026 · Fusion42 review

The FDA approved the combination of belzutifan and lenvatinib for treating advanced clear cell renal cell carcinoma (ccRCC) following progression after PD-1/PD-L1 inhibitor therapy, offering a new treatment option that includes patients with prior VEGFR-TKI exposure.

This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 24 Sep 2026 and 28 Sep 2026.

◆ ◆ The Wire takeaway

Belzutifan plus lenvatinib clearance opens a new treatment path post-immunotherapy failure in kidney cancer. You can now target patients progressing after PD-1/PD-L1 inhibitors, expanding your addressable market.

◆ Coverage

8 sources · first reported 24 Sep 2026 · latest 28 Sep 2026

◆ Topics

Biotechccrccfda-approvalcancer-treatmentdrug-combination